| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | esxA |
| Uniprot No | Q6GCJ0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-97aa |
| 氨基酸序列 | MAMIKMSPEEIRAKSQSYGQGSDQIRQILSDLTRAQGEIAANWEGQAFSRFEEQFQQLSPKVEKFAQLLEEIKQQLNSTADAVQEQDQQLSNNFGLQ |
| 预测分子量 | 24.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于esxA重组蛋白的典型研究文献(信息经简化处理)：
1. **文献名称**：Expression and purification of Mycobacterium tuberculosis ESAT-6 (esxA) in Escherichia coli
**作者**：Pym AS et al.
**摘要**：该研究成功在大肠杆菌中表达并纯化结核分枝杆菌esxA重组蛋白，验证其抗原性，为结核病血清学诊断试剂开发提供基础。
2. **文献名称**：Structural insights into the ESX-1 secretion system: the esxA- esxB heterodimer
**作者**：Renshaw PS et al.
**摘要**：通过X射线晶体学解析esxA与esxB重组蛋白形成的复合物结构，揭示其在细菌膜转运中的关键相互作用位点。
3. **文献名称**：Recombinant esxA protein as a candidate for subunit vaccine against tuberculosis
**作者**：Lin MY et al.
**摘要**：评估esxA重组蛋白在小鼠模型中的免疫原性，显示其可诱导Th1型免疫应答，具有作为结核亚单位疫苗组分的潜力。
注：实际文献检索建议通过PubMed/Web of Science等平台，使用关键词"recombinant esxA protein"+"Mycobacterium"获取最新研究。部分经典研究发表年份较早(如2003-2010年间)，近年研究多聚焦于该蛋白的纳米颗粒疫苗开发或CRISPR干扰应用。
**Background of EsxA Recombinant Protein**
EsxA, also known as ESAT-6 (6 kDa early secretory antigenic target), is a small secretory protein produced by *Mycobacterium tuberculosis* (Mtb), the causative agent of tuberculosis (TB). It is a key virulence factor encoded within the *esx-1* gene cluster, which is part of the ESX-1 secretion system. EsxA plays a critical role in Mtb pathogenesis by disrupting host cell membranes, facilitating bacterial escape from phagosomes into the cytosol, and modulating immune responses. Its immunodominant nature makes it a prominent target for TB diagnostics and vaccine development.
Recombinant EsxA protein is produced through genetic engineering, typically by cloning the *esxA* gene into expression vectors (e.g., *E. coli* or yeast systems) followed by purification. This approach allows large-scale production of the protein without requiring pathogenic Mtb cultures, enhancing safety and accessibility. Recombinant EsxA retains antigenic properties, enabling its use in immunological studies, such as T-cell activation assays and interferon-gamma release assays (IGRAs) for TB diagnosis.
Research on EsxA also focuses on its role in vaccine design. Subunit vaccines incorporating recombinant EsxA, often combined with other antigens like CFP-10. aim to elicit protective immune responses. However, challenges remain, including balancing immunogenicity with safety and avoiding excessive inflammatory responses.
Overall, EsxA recombinant protein serves as a vital tool for understanding TB pathogenesis, improving diagnostics, and advancing vaccine strategies, reflecting its dual significance in microbial virulence and host immunity.
×
